{"bill": {"@star-print": "no-star-print", "#text": "\n  ", "form": {"current-chamber": {"#tail": "\n    ", "@display": "no", "#text": "IN THE SENATE OF THE UNITED STATES"}, "#text": "\n", "congress": {"#tail": "\n    ", "@display": "yes", "#text": "113th CONGRESS"}, "#tail": "\n  ", "legis-num": {"#tail": "\n    ", "@display": "yes", "#text": "S. 2338"}, "official-title": {"#tail": "\n  ", "@display": "yes", "#text": "To reauthorize the United States Anti-Doping Agency, and for other purposes."}, "@display": "yes", "session": {"#tail": "\n    ", "@display": "yes", "#text": "2d Session"}, "legis-type": {"#tail": "\n    ", "@display": "yes", "#text": "AN ACT"}}, "attestation": {"#tail": "\n  ", "attestation-group": {"#tail": "\n  ", "role": {"#tail": "\n    ", "#text": "Secretary"}, "#text": "\n      ", "attestor": {"#tail": "\n      ", "@display": "no"}, "attestation-date": {"#tail": "\n      ", "@date": "20141211", "#text": "Passed the Senate December 11, 2014.", "@chamber": "Senate"}}, "#text": "\n    "}, "@stage-count": "1", "@bill-stage": "Engrossed-in-Senate", "@bill-type": "olc", "endorsement": {"#tail": "\n", "@display": "yes"}, "@dms-id": "A1", "@public-private": "public", "legis-body": {"#tail": "\n  ", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n    ", "quote": {"short-title": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "act", "#text": "United States Anti-Doping Agency Reauthorization Act", "@value": "United States Anti-Doping Agency Reauthorization Act", "@proposed": "true"}, "#text": "\n            "}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the\n\t\t  ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "#text": "\n      ", "@id": "S1", "@commented": "no"}, {"@section-type": "subsequent-section", "#tail": "\n    ", "text": {"#tail": "\n      ", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 701 of title VII of the Office of\nNational Drug Control Policy Reauthorization Act of 2006", "@value": "Office of National Drug Control Policy Reauthorization Act of 2006/s:701"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n        ", "@entity-type": "uscode", "#text": "21 U.S.C. 2001", "@value": "usc/21/2001"}, "@parsable-cite": "usc/21/2001", "#text": "\n          ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Prohibit performance-enhancing methods", "@display-inline": "yes-display-inline"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n      ", "#text": "in subsection (a), by striking paragraph (4); and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "id67FFE25C78864C5BBC61262C221750E4", "@commented": "no"}, {"@id": "idBE0E2D9201E64C07B0A568FADD9D6F29", "#tail": "\n    ", "text": {"#tail": "\n        ", "#text": "in subsection (b)\u2014", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "@display-inline": "no-display-inline", "#text": "\n        ", "subparagraph": [{"#tail": "\n        ", "text": {"#tail": "\n        ", "quote": [{"#tail": " after ", "#text": "and be recognized worldwide as the independent\n\t\t\t national anti-doping organization for the United States"}, {"#tail": ";", "#text": "Committee"}], "#text": "in paragraph (1), by inserting ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(A)"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "id9AF1207214F24F6FA0752AA79D4ECA02", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "quote": [{"#tail": " and inserting ", "#text": ", or performance-enhancing genetic modifications accomplished\nthrough gene-doping"}, {"#tail": ";", "#text": "or prohibited performance-enhancing methods adopted by the Agency"}], "#text": "in paragraph (2), by striking ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(B)"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "id68D8F8A57B904D18B32C525F4D5FF005", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "quote": [{"#tail": " and inserting ", "#text": ", or performance-enhancing genetic modifications accomplished\nthrough gene-doping"}, {"#tail": ";", "#text": "or prohibited performance-enhancing methods adopted by the Agency"}], "#text": "in paragraph (3), by striking ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(C)"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "idBE0156A543DD4F7B9E097C45AB4008A3", "@commented": "no"}, {"#tail": "\n        ", "text": {"#tail": "\n        ", "quote": [{"#tail": " and inserting ", "#text": "and the prevention of use of performance-enhancing drugs, or performance-enhancing\ngenetic modifications accomplished through gene-doping by\nUnited States amateur athletes; and"}, {"#tail": "; and", "#text": ", and the prevention of use by United States amateur athletes of performance-enhancing drugs or\n\t\t\t prohibited performance-enhancing methods adopted by the Agency."}], "#text": "in paragraph (4), by striking ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(D)"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "id2364B9843A2D4422AB185CF3B9DDD54E", "@commented": "no"}, {"#tail": "\n      ", "text": {"#tail": "\n        ", "#text": "by striking paragraph (5).", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(E)"}, "@display-inline": "no-display-inline", "#text": "\n          ", "@id": "id7112A90410674649A373CEF75934FC31", "@commented": "no"}], "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n      ", "@id": "id5A35AFD1FC254879B52B44DE5DCB9A89", "@commented": "no"}, {"@section-type": "subsequent-section", "#tail": "\n  ", "text": {"#tail": "\n      ", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended to read as\n\t\t\t follows:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 703 of title VII of the Office of\nNational Drug Control Policy Reauthorization Act of 2006", "@value": "Office of National Drug Control Policy Reauthorization Act of 2006/s:703"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n        ", "@entity-type": "uscode", "#text": "21 U.S.C. 2003", "@value": "usc/21/2003"}, "@parsable-cite": "usc/21/2003", "#text": "\n          ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "Authorization of appropriations", "@display-inline": "yes-display-inline"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n    ", "section": {"#text": "\n          ", "@section-type": "subsequent-section", "#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "703."}, "header": {"#tail": "\n          ", "#text": "Authorization of appropriations", "@display-inline": "yes-display-inline"}, "@display-inline": "no-display-inline", "{http://namespaces.cato.org/catoxml}block-entity": {"#tail": "\n        ", "text": {"#tail": "\n          ", "#text": "There are authorized to be appropriated ", "{http://namespaces.cato.org/catoxml}property": {"#tail": "\u2014", "#text": "to the United States\nAnti-Doping Agency", "@name": "purpose"}, "@display-inline": "no-display-inline"}, "@entity-type": "auth-auth-approp", "paragraph": [{"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ";", "#text": "for fiscal year 2014, $11,300,000", "@amount": "11300000", "@year": "2014"}, "#text": "\n                ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(1)"}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "idB5E00E0013A04377850168391169A528", "@commented": "no"}, {"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ";", "#text": "for fiscal year 2015, $11,700,000", "@amount": "11700000", "@year": "2015"}, "#text": "\n                ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(2)"}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "idC32D83DBA49A4F478C8286AF4070854D", "@commented": "no"}, {"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ";", "#text": "for fiscal year 2016, $12,300,000", "@amount": "12300000", "@year": "2016"}, "#text": "\n                ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(3)"}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "id1C6F7C153ED446F495D0FD0F7323A35B", "@commented": "no"}, {"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ";", "#text": "for fiscal year 2017, $12,900,000", "@amount": "12900000", "@year": "2017"}, "#text": "\n                ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(4)"}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "id7C191027B347483692BD8763BCBCEC0C", "@commented": "no"}, {"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ";", "#text": "for fiscal year 2018, $13,500,000", "@amount": "13500000", "@year": "2018"}, "#text": "\n                ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(5)"}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "id1CF7C77D7BF3482E90315DF820970A3B", "@commented": "no"}, {"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": "; and", "#text": "for fiscal year 2019, $14,100,000", "@amount": "14100000", "@year": "2019"}, "#text": "\n                ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(6)"}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "id962236106A314BFDB98798ACE68A7DEF", "@commented": "no"}, {"#tail": "\n          ", "text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}funds-and-year": {"#tail": ".", "#text": "for fiscal year 2020, $14,800,000", "@amount": "14800000", "@year": "2020"}, "#text": "\n                ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(7)"}, "@display-inline": "no-display-inline", "#text": "\n            ", "@id": "id318AA7D7B17E40B79DB888401DB36197", "@commented": "no"}], "#text": "\n            "}, "@id": "idA19E869EEBB3459490ED5DBEB40BCC59", "@commented": "no"}, "@display-inline": "no-display-inline", "#text": "\n        ", "@id": "id0EF0A1EFB4194B42BBF2D4EA1B7E9B36"}, "@display-inline": "no-display-inline", "#text": "\n      ", "@id": "idAE567C321CBD4BF29D2DDE71543ED884", "@commented": "no"}], "#text": "\n    ", "@display-enacting-clause": "yes-display-enacting-clause"}, "@public-print": "no", "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 S2338 ES: United States Anti-Doping Agency Reauthorization Act"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. Senate"}, "#text": "\n"}, "#text": "\n"}}}